Tridek-One is a spin-off from Inserm that develops first-in-class therapeutic agonistic monoclonal antibodies targeting immune checkpoint inhibitory receptors for the treatment of autoimmune and inflammatory diseases.
The company primarily focuses on the research and development of first-in-class anti-CD31 agonistic modalities designed to restore the immune balance.
Anti-CD31 agonistic mAbs have the potential to provide targeted immunomodulatory activity with a favorable safety profile in diseases with high unmet clinical need.
Tridek-One has initiated a discovery program which targets another ITIM receptor, fully leveraging its understanding of inhibitory checkpoint receptor modulation and agonistic monoclonal antibodies engineering.
Our company is financed by leading European investors and led by an experienced management team.
Company Details
- Employees
- 14
- Founded
- 2018
- Address
- 4, Rue Thénard, Paris,île-De-France 75005,france
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- tridekone.com
- HQ
- Paris, Île-de-France
Tridek-One Questions
Tridek-One's website is tridekone.com
Tridek-One's LinkedIn profile is https://fr.linkedin.com/company/tridek-one
Tridek-One has
14 employees.
View email and phone details for 14
employees at Tridek-One.
Tridek-One's industry is
Biotechnology Research
Tridek-One's top competitors are
Phaxiam Therapeutics,
Thabor Therapeutics,
Perseo Pharma Ag,
Amal Therapeutics,
Adbio Partners,
Twinedge Bioscience,
Araris Biotech Ag,
Royal Society Of Biology,
Calida Therapeutics,
Advent Life Sciences.
Tridek-One's categories are Biotechnology Research
Tridek-One's founding year is 2018
